OUR TEAM
Meet Our Team
Dr. Hasib Salah-Uddin – Chief Executive Officer
Dr. Hasib Salah-Uddin is the Founder, CEO, and Chief Scientific Officer of Vayuna Therapeutics, where he leads the development of first-in-class antibody-drug conjugates (ADCs) and parenteral therapeutics targeting EGFR-high treatment-resistant cancers. His scientific career spans over two decades across major pharmaceutical companies, world-class academic research institutions, and entrepreneurial biotech ventures — with deep expertise in GPCR drug discovery, high-throughput screening, epigenetic therapeutics, and translational pharmacology.
Education
Ph.D., Medical Sciences – University of Aberdeen
B.Sc. (Hons), Biochemistry – University College London
Daniel Larsen, CFA - Vice President of Business Development
Daniel Larsen is a seasoned investment professional with over 25 years of experience managing capital for high-net-worth individuals and institutional clients. He has held leadership roles at premier financial institutions including JP Morgan, Morgan Stanley, and UBS, where he specialized in portfolio construction, risk management, and strategic advisory.
Dan began his career at Boston Research and Management through a referral from his graduate school mentor. Over six years, he advanced from investment analyst to Chief Investment Officer, where he oversaw $500 million in equity and fixed income assets. His disciplined, research-driven approach and fiduciary mindset have made him a trusted advisor across market cycles.
In parallel to his financial career, Dan later founded and scaled a successful restoration company, bringing operational rigor and entrepreneurial insight to business building. He continues to advise on strategic financial matters while remaining active in his local community, teaching breathwork and meditation as part of his passion for wellness.
Education
MBA, Finance – Boston College
BA, Philosophy – Colgate University
Dr. Brown – Scientific Advisor
Dr. Brown is a distinguished cancer biologist and serial biotech entrepreneur with over 30 years of experience in oncology drug discovery and development. He played a pivotal role in the advancement and FDA approval of Synribo®(omacetaxine mepesuccinate), a plant-derived therapy for chronic myeloid leukemia.
He was the founder and President of ChemGenex Therapeutics, which merged to form ChemGenex Pharmaceuticals (ASX:CXS / NASDAQ:CXSP), and previously served as Chief Scientific Officer and Director at DelMar Pharmaceuticals (now Kintara Therapeutics, NASDAQ:KTRA). He has also chaired the Board of Mountain View Pharmaceuticals. Earlier in his career, Dr. Brown co-founded Matrix Pharmaceutical, Inc., where he held executive roles in scientific affairs and discovery research.
In academia, Dr. Brown held faculty positions at Harvard Medical School and conducted research at Stanford University School of Medicine, contributing to advances in radiology and cancer imaging.